Behringwerke Aktiengesellschaft

Csl Behring Gmbh

Hoechst Aktiengesellschaft

Aventis Behring Gmbh

The General Hospital Corporation

Csl Behring Lengnau Ag

Zlb Behring Gmbh

Laboratoires Hoechst

Hauser, Hans-peter

Dickneite, Gerhard

Weimer, Thomas

Kröz, Monika

Gerhard Dickneite

Hans-Ulrich Schorlemmer

Hans H Sedlacek

Ingo Pragst

Hans-Harald Sedlacek

Stefan Schulte

Marc Nolte

Stefan Zeitler

Cenek Kolar

J&uuml;rgen R&ouml;misch

Peter Gronski

Klaus Bosslet

Walter Durckheimer

Hubert Metzner

Noel J De Souza

Alihussein N Dohadwalla

Stephen Poole

Michael Limbert

Harald Stauss

Rainer Koschinsky

Bernhard Vohwinkel

Guido Stoll

Pauline Sxouter

Henrique Lessa

Elaine Gray

Thorsten Haas

Ralph Weissleder

Wilfried Schwab

Bansi Lal

Robert R Bartlett

Ulrich Gebert

Thomas Weimer

Hans-Peter Hauser

Werner Stuber

Jurgen Blumbach

Richard H Rupp

Gerhard Seemann

Jean-Claude Jacquesy

Hans P Kraemer

Claude Monneret

Richard Lathe

Axel Zeeck

Michel Koch

Manfred Gerken

Jean-Pierre Gesson

Gerd Zettlmeissl

Ulrich Grundmann

Sabine Pestel

Jean-Claude Florent

Francedillaois Tillequin

Hans U Schorlemmer

Hans Zahner

Martine Mondon

Bernhard Nieswandt

Karl-Heinz Scheunemann

Ralf Thiericke

Sujata Vasudev Bhat

Michael Moses

Meng Li

Matthias P Nahrendorf

Uwe Kalina

Christoph Kleinschnitz

Martin Reers

Werner St Uber

J Org Czech

Jurgen Lindner

Dieter Hoffman

Ramchandra G Naik

Gilbert Gaudel

Brigitte Renoux

Sadashiv M Mandrekar

Virbala Shah

Roland Kurrle

Eric-Paul P&acirc;ques

Robert Bartlett

Austin Smith

Monika Kroez

StuWerner

Matthias Nahrendorf

Monika Kröz

Darrell Sleep

The invention relates to a modified VWF molecule for use in the treatment of a blood coagulation disorder.

Modified von Willebrand factor having improved half-life

An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.

Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces

Silent brain ischemia (SBI) or ischemia of other organs can result from an embolism that is introduced into the arterial system during a medical procedure. The application provides a method of administering a FXII inhibitor in a patient receiving a medical procedure and animal models useful for studying ischemia including SBI and ischemia in other organs, and for evaluating candidate therapeutics.

Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs

The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury and spinal cord injury. Preferably the secondary edema of the CNS is a secondary brain edema. Another subject of the present invention is the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier. And a third subject is a plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury.

Use of C1-inhibitor for the treatment of secondary edema of the central nervous system

The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.

von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes

The field of the invention is the treatment of acquired bleeding, a clinical condition associated with severe traumatic, peri- or post-operative bleeding. A novel treatment is proposed in which synergistic pro-coagulatory properties of Prothrombin Complex Concentrates (PCC) together with medicaments comprising FVIII and/or vWF are exploited.

Synergistic therapeutic use of prothrombin complex concentrates with FVIII  concentrates

The field of the invention is the treatment of acquired bleeding, a clinical condition associated with severe traumatic, peri- or post-operative bleeding. A novel treatment is proposed in which synergistic procoagulatory properties of Prothrombin Complex Concentrates (PCC) together with medicaments comprising FVIII and/or vWF are exploited.

Synergistic therapeutic use of Prothrombin Complex Concentrates with FVIII concentrates

The use of a tissue glue comprising a stabilized fibrinogen preparation, which can be stored in the liquid or frozen state and comprises a chaotropic substance, and a thrombin preparation, for reducing or preventing tissue adhesions, is described.

Tissue glue with improved antiadhesive properties

A pharmaceutical preparation is described while is useful for the treatment of inflammatory processes being accompanied by an increased distribution of cytokines and/or tissue factor in the human body, which preparation contains Antithrombin III as active ingredient.

Pharmaceutical preparation for the treatment of inflammatory processes

The invention relates to the use of complement inhibitors, especially of C1 inactivator or of factors I or H, for the preparation of a pharmaceutical and for the prophylaxis and therapy of chronic inflammatory intestinal disorders, inflammatory skin disorders and purpura.

Use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura

The invention provides a transgenic mouse which is heterozygous or homozygous for an at least partially defective coagulation factor XIII gene.

Transgenic coagulation factor XIII defective animal and its use for testing wound healing and bleeding

Methods are disclosed for treatment of hyperreactive inflammatory diseases of humans and animals comprising administering a pharmaceutically effective amount of deoxyspergualin to a human or an animal.

Use of deoxyspergualin for preparing a pharmaceutical for treating

Growing community of inventors

Marburg, Germany

Gerhard Dickneite